Case report
SU-011248, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, controls chronic psoriasis

https://doi.org/10.1016/j.trsl.2007.01.003Get rights and content

Section snippets

Discussion

To the authors’ knowledge, this case report is the first to document the improvement in chronic cutaneous psoriasis after systemic therapy with the VEGFR-TK inhibitor, SU-011248, during second-line monotherapy for treatment of recurrent metastatic RCC. Exacerbation of psoriasis during IFN-α therapy has been previously reported,1 and the initial improvement in psoriasis during the first cycle of sunitinib therapy could have been related to the withdrawal of IFN-α treatment. However, subsequent

Conclusion

VEGFR-TK inhibitors may have a therapeutic effect in chronic cutaneous psoriasis. Additional collection of similar case reports is encouraged to provide a rationale for conducting a clinical study of angiogenesis inhibitors in the treatment of refractory psoriasis.

First page preview

First page preview
Click to open first page preview

References (18)

There are more references available in the full text version of this article.

Cited by (26)

  • Nintedanib ameliorates imiquimod-induced psoriasis in mice by inhibiting NF-κB and VEGFR2 signaling

    2021, International Immunopharmacology
    Citation Excerpt :

    In addition, nintedanib inhibited angiogenesis by downregulating the activation of p-VEGFR2 in IMQ-induced mice. Several case studies reported the attenuation of psoriatic disease in patients with cancer after treatment with anti-VEGFA antibodies or anti-VEGFA receptor small-molecule inhibitors [11,19–22]. The use of anti-VEGFA inhibitors in different mouse models of psoriasis induced the regression of the psoriasis phenotypes, including epidermal hyperproliferation, thickness, altered differentiation, dermal immune infiltration, and increased angiogenesis [13,14,34,35].

  • Topical Sunitinib ointment alleviates Psoriasis-like inflammation by inhibiting the proliferation and apoptosis of keratinocytes

    2018, European Journal of Pharmacology
    Citation Excerpt :

    VEGF receptor tyrosine kinase inhibitors can effectively treat psoriasis, this may be attributed to the antiangiogenic activity of Sunitinib by inhibition of VEGF receptors (Su et al., 2009). EGF could induce HaCaT cells to a highly proliferation state (Keshtgarpour and Dudek, 2007; Jiang et al., 2012). In this study, therefore, we chose EGF co-cultured HaCat cells (HaCaT/E), which was used as a cell model of psoriasis keratinocyte, to imitate the highly proliferative state of psoriatic keratinocytes.

  • Angiogenesis in Dermatology – Insights of Molecular Mechanisms and Latest Developments

    2017, Actas Dermo-Sifiliograficas
    Citation Excerpt :

    Different case reports with angiogenesis-inhibitors given for cancer therapy in patients with psoriasis have been published. Sunitinib (Sutent), a potent VEGFR – inhibitor in the treatment for renal cell carcinoma, could almost clear chronic large psoriatic plaques in a patient, as reported in 2007 by Keshtagarpour and Arkadius.24 In 2009 another report of a patient presenting complete remission of chronic psoriasis while receiving Bevacizumab (anti-VEGF Ab) for colon cancer therapy was published.25

  • Cannabinoids: Possible agents for treatment of psoriasis via suppression of angiogenesis and inflammation

    2017, Medical Hypotheses
    Citation Excerpt :

    According to Datta-Mitra’s study on a PS patient with renal cancer which was treated by an anti-VEGF monoclonal anti-body (Bevacizumab®), a complete remission of PS and psoriatic arthritis was observed [42]. Additionally, in two cases with psoriasis who received Sunitinib (a tyrosine kinase inhibitor of VEGFR) an acceptable improvement in their condition was observed [43,44]. Monoclonal antibodies against TNF-α such as Infliximab® has been confirmed as a systemic treatment for adults’ psoriasis by food and drug administration (FDA) in 2006 [45].

  • Tyrosine kinases in inflammatory dermatologic disease

    2011, Journal of the American Academy of Dermatology
View all citing articles on Scopus
View full text